Wedbush Downgrades Intellia Therapeutics (NTLA) to Neutral

February 14, 2020 6:49 AM EST
Get Alerts NTLA Hot Sheet
Price: $141.78 +3.47%

Rating Summary:
    16 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 8
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten downgraded Intellia Therapeutics (NASDAQ: NTLA) from Outperform to Neutral with a price target of $16.00 (from $21.00).

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $15.51 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades